Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS).

Rheumatology international - 1 Nov 2015

La Torre Francesco, Muratore Maurizio, Vitale Antonio, Moramarco Fulvio, Quarta Laura, Cantarini Luca

Abstract excerpt

Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) is an autosomal dominantly inherited autoinflammatory disease caused by mutations in the TNFRSF1A gene. Treatment is aimed at preventing acute disease attacks, improving quality of life, and preventing long-term complications such as systemic reactive amyloidosis. Biologic agents have significantly improved TRAPS management. In particular,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Hereditary Autoinflammatory Diseases

Share to Immunosuppressive Agents

Share to Receptors, Tumor Necrosis Factor, Type I

Share to Treatment Outcome

Source

Identifiers

PMID: 26048626
DOI: 10.1007/s00296-015-3305-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS).PMID 26048626Read ↗

Canakinumab for the treatment of TNF-receptor associated periodic syndrome.Semantic proximity Read ↗

A Case Presenting with the Clinical Characteristics of Tumor Necrosis Factor (TNF) Receptor-associated Periodic Syndrome (TRAPS) without TNFRSF1A Mutations Successfully Treated with Tocilizumab.Semantic proximity Read ↗

Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate.Semantic proximity Read ↗

The most recent advances in pathophysiology and management of tumour necrosis factor receptor-associated periodic syndrome (TRAPS): personal experience and literature review.Semantic proximity Read ↗

[Tumor necrosis receptor associated periodic syndrome (TRAPS): State of the art].Semantic proximity Read ↗

Efficacy of anakinra in an adult patient with recurrent pericarditis and cardiac tamponade as initial manifestations of tumor necrosis factor receptor-associated periodic syndrome due to the R92Q TNFRSF1A variant.Semantic proximity Read ↗

The First Case of a Korean Patient with a Mutation-Confirmed Tumor Necrosis Factor Receptor-Associated Periodic Syndrome.Semantic proximity Read ↗

Revisiting TNF Receptor-Associated Periodic Syndrome (TRAPS): Current Perspectives.Semantic proximity Read ↗

Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.Semantic proximity Read ↗

Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome.Semantic proximity Read ↗

Setting up TRAPS.Semantic proximity Read ↗

TNF-receptor-associated periodic syndrome (TRAPS): an autosomal dominant multisystem disorder.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.